Controlled Substance Act & FDCA Violations Defense Attorneys

Controlled Substances Act & FDCA Violations Defense Overview

Allegations involving the Controlled Substances Act (CSA) or the Federal Food, Drug, and Cosmetic Act (FDCA) place individuals and organizations squarely in the government’s crosshairs. These are not routine regulatory matters—they are federal enforcement actions that can threaten careers, businesses, professional licenses, and personal freedom.

At Chapman, Dowling & Mallek, we represent physicians, pharmacists, healthcare executives, pharmaceutical companies, and regulated professionals facing some of the most aggressive investigations brought by the DEA, FDA, DOJ, and U.S. Attorney’s Offices nationwide. These cases demand far more than a general criminal defense approach. They require deep regulatory fluency, command of medical and scientific evidence, and the ability to dismantle complex federal enforcement theories—often before charges are ever filed.

What CSA & FDCA Defense Means in Practice

From a legal standpoint, Controlled Substances Act and FDCA defense is not a single tactic—it is a coordinated, precision-driven strategy designed to neutralize federal exposure at every stage of an investigation.

Controlled Substances Act (21 U.S.C. § 801 et seq.)

The CSA governs the manufacture, prescribing, dispensing, storage, and distribution of controlled substances. Federal prosecutors often allege that a provider or entity operated outside the “usual course of professional practice” or without a “legitimate medical purpose.”

Effective CSA defense focuses on:

• Clinical decision-making and medical necessity
  
• Prescribing intent and professional judgment
  
• DEA compliance and registration issues
  
• Recordkeeping and inventory controls
  
• Allegations of diversion or overprescribing

These cases frequently hinge on subjective interpretations of medical care—making early, strategic intervention critical.

Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.)

The FDCA empowers the FDA to regulate drug safety, manufacturing, labeling, and marketing. Criminal FDCA cases are often built on highly technical allegations that prosecutors oversimplify for leverage.

Common defense issues include:

• Misbranding and labeling disputes
  
• Alleged adulteration or manufacturing violations
  
• Off-label promotion allegations
  
• Failure to report adverse events
  
• Distribution or importation of unapproved products

At Chapman, Dowling & Mallek, we challenge these cases at their foundation—scientifically, procedurally, and constitutionally.

Common CSA & FDCA Allegations We Defend

Healthcare Professionals

• Alleged “pill mill” or improper prescribing cases
  
• Dispensing outside professional standards
  
• DEA audits and registration revocation proceedings
  
• Recordkeeping or reporting violations
  
• Diversion allegations involving staff or third parties

Pharmaceutical & Medical Product Companies

• Off-label marketing investigations
  
• Misbranding and adulteration claims
  
• Manufacturing and quality control enforcement
  
• Importation of unapproved or misclassified products
  
• Failure to register or comply with FDA requirements

Individuals

• Possession with intent to distribute
  
• Federal drug trafficking allegations
  
• Conspiracy charges tied to healthcare or pharmaceutical operations

Who Investigates These Cases

CSA and FDCA matters are rarely handled by a single agency. Investigations often involve coordinated federal task forces, including:

• Drug Enforcement Administration (DEA)
  
• FDA – Office of Criminal Investigations (OCI)
  
• Federal Bureau of Investigation (FBI)
  
• HHS Office of Inspector General (OIG)
  
• State medical, pharmacy, and professional licensing boards
  
• U.S. Attorney’s Offices

Parallel criminal, civil, and administrative proceedings are common—and missteps in one arena can severely damage another.

Potential Penalties and Exposure

CSA and FDCA violations carry some of the most severe penalties in federal law:

Criminal Consequences

• Lengthy federal prison sentences
  
• Massive fines and restitution
  
• Criminal forfeiture of assets

Civil & Administrative Sanctions

• Civil Monetary Penalties (CMPs)
  
• Exclusion from Medicare and Medicaid
  
• Loss or suspension of professional licenses
  
• DEA registration revocation
  
• Corporate Integrity Agreements (CIAs)

For professionals and executives, these penalties often represent the end of a career—not just a legal setback.

Overlapping Healthcare Fraud Exposure

CSA and FDCA cases frequently trigger broader federal fraud allegations, including:

• False Claims Act (FCA) investigations and qui tam lawsuits
• Anti-Kickback Statute enforcement
• Stark Law scrutiny
• Federal Healthcare Fraud (18 U.S.C. § 1347) charges

A disciplined defense strategy must account for every layer of exposure—not just the headline charge.

Need help now? Call our healthcare fraud defense attorneys today.

Healthcare professionals and organizations trust us because we understand federal enforcement tactics, move quickly to protect careers and licenses, and focus on achieving the best possible outcome with minimal disruption to professional and business operations.
346-CHAPMAN

Why Clients Trust Chapman, Dowling & Mallek

CSA and FDCA cases are won—or quietly resolved—by law firms that understand how federal agencies actually build and pressure these cases.

Clients turn to Chapman, Dowling & Mallek because we:

• Intervene early, often before charges are filed
  
• Understand the science, medicine, and regulatory mechanics behind the allegations
  
• Anticipate DOJ and agency enforcement strategies
  
• Protect professional licenses and federal program eligibility
  
• Pursue quiet resolutions whenever possible—and litigate aggressively when necessary

When federal regulators and prosecutors are scrutinizing your practice, products, or prescribing decisions, experience is not optional. It is decisive.

Government & Regulatory Sources:

1. U.S. Drug Enforcement Administration (DEA) – Diversion Control Division: https://www.deadiversion.usdoj.gov/
2. U.S. Food & Drug Administration (FDA) – Laws & Regulations: https://www.fda.gov/regulatory-information/laws-regulations-and-guidance
3. U.S. Department of Justice (DOJ) – False Claims Act – Whistleblower Protection: https://www.justice.gov/civil/false-claims-act
4. U.S. Department of Health & Human Services (HHS) – Office of Inspector General (OIG) – Fraud & Abuse Laws: https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/